FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

SD Kemp

Research Profile

Chemicals & Drugs

Living Beings

HIV-1

Physiology

Concepts & Ideas

Molecular Sequence Data

Anatomy

Disorders

HIV Infections

Procedures

Drug Therapy, Combination

Co-author Network

Publications

TOP 3
P Richard Harrigan; Mahboob Salim; David K Stammers; Brian Wynhoven; Zabrina L Brumme; Paula McKenna; Brendan Larder; SD Kemp
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Kurt Hertogs; Stuart Bloor; SD Kemp; Christel Van den Eynde; TM Alcorn; Rudi Pauwels; M Van Houtte; Schlomo Staszewski; Veronica Miller; Brendan Larder
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
Brendan Larder; Stuart Bloor; SD Kemp; Kurt Hertogs; R L Desmet; Veronica Miller; M Sturmer; Schlomo Staszewski; J Ren; David K Stammers; D I Stuart; Rudi Pauwels
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of SD Kemp (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: P Richard Harrigan; Mahboob Salim; David K Stammers; Brian Wynhoven; Zabrina L Brumme; Paula McKenna; Brendan Larder; SD Kemp
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Journal of virology 2002;76(13):6836-40.
2000: Kurt Hertogs; Stuart Bloor; SD Kemp; Christel Van den Eynde; TM Alcorn; Rudi Pauwels; M Van Houtte; Schlomo Staszewski; Veronica Miller; Brendan Larder
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
AIDS (London, England) 2000;14(9):1203-10.
1999: Brendan Larder; Stuart Bloor; SD Kemp; Kurt Hertogs; R L Desmet; Veronica Miller; M Sturmer; Schlomo Staszewski; J Ren; David K Stammers; D I Stuart; Rudi Pauwels
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
Antimicrobial agents and chemotherapy 1999;43(8):1961-7.
1998: Veronica Miller; Andrew Phillips; Carsten Rottmann; Schlomo Staszewski; Rudi Pauwels; Kurt Hertogs; Marie-Pierre de Bethune; SD Kemp; Stuart Bloor; P Richard Harrigan; Brendan Larder
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
The Journal of infectious diseases 1998;177(6):1521-32.
1998: SD Kemp; C Shi; Stuart Bloor; P Richard Harrigan; J W Mellors; Brendan Larder
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
Journal of virology 1998;72(6):5093-8.
1998: Veronica Miller; Martin Stürmer; Schlomo Staszewski; Bettina Gröschel; Kurt Hertogs; Marie-Pierre de Bethune; Rudi Pauwels; P Richard Harrigan; Stuart Bloor; SD Kemp; Brendan Larder
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
AIDS (London, England) 1998;12(7):705-12.
1996: P Richard Harrigan; I Kinghorn; Stuart Bloor; SD Kemp; I Nájera; A Kohli; Brendan Larder
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Journal of virology 1996;70(9):5930-4.
1996: Brendan Larder; A Kohli; Stuart Bloor; SD Kemp; P Richard Harrigan; Robert T Schooley; J M Lange; K N Pennington; Marty St Clair
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Journal of virology 1996;70(9):5922-9.
1995: Brendan Larder; SD Kemp; P Richard Harrigan
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Science (New York, N.Y.) 1995;269(5224):696-9.
1993: Brendan Larder; A Kohli; Kellam Paul; SD Kemp; M Kronick; R D Henfrey
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing.
Nature 1993;365(6447):671-3.
1993: Brendan Larder; Kellam Paul; SD Kemp
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Nature 1993;365(6445):451-3.
1993: M Tisdale; SD Kemp; N R Parry; Brendan Larder
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(12):5653-6.
1992: S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; SD Kemp; Brendan Larder
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.
The Journal of biological chemistry 1992;267(22):15789-94.
1991: Brendan Larder; K E Coates; SD Kemp
Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
Journal of virology 1991;65(10):5232-6.
1991: Marty St Clair; J L Martin; G Tudor-Williams; M C Bach; CL Vavro; D M King; Kellam Paul; SD Kemp; Brendan Larder
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science (New York, N.Y.) 1991;253(5027):1557-9.
1991: D M Lowe; V Parmar; SD Kemp; Brendan Larder
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase.
FEBS letters 1991;282(2):231-4.
1991: Brendan Larder; Kellam Paul; SD Kemp
Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
AIDS (London, England) 1991;5(2):137-44.
1989: Brendan Larder; SD Kemp
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Science (New York, N.Y.) 1989;246(4934):1155-8.
1989: Brendan Larder; SD Kemp; D J Purifoy
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(13):4803-7.
1987: Brendan Larder; SD Kemp; G Darby
Related functional domains in virus DNA polymerases.
The EMBO journal 1987;6(1):169-75.